1. Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells
- Author
-
A-Young Nam, Sang Hoon Joo, Quan T. Khong, Jisu Park, Na Yeong Lee, Seung-On Lee, Goo Yoon, Jin Woo Park, MinKyun Na, and Jung-Hyun Shim
- Subjects
Deoxybouvardin ,Reactive oxygen species ,Non-small cell lung cancer ,EGFR ,MET ,AKT ,Medicine ,Science - Abstract
Abstract Non-small cell lung cancer (NSCLC) remains a significant challenge, as it is one of the leading causes of cancer-related deaths, and the development of resistance to anticancer therapy makes it difficult to treat. In this study, we investigated the anticancer mechanism of deoxybouvardin (DB), a cyclic hexapeptide, in gefitinib (GEF)-sensitive and -resistant NSCLC HCC827 cells. DB inhibited the viability and growth of HCC827 cells in a concentration- and time-dependent manner. In vitro kinase assay showed DB inhibited epidermal growth factor receptor (EGFR), mesenchymal–epithelial transition (MET), and AKT, and their phosphorylation was suppressed in HCC827 cells treated with DB. A molecular docking model suggested that DB interacts with these kinases in the ATP-binding pockets. DB induces ROS generation and cell cycle arrest. DB treatment of HCC827 cells leads to mitochondrial membrane depolarization. The induction of apoptosis through caspase activation was confirmed by Z-VAD-FMK treatment. Taken together, DB inhibited the growth of both GEF-sensitive and GEF-resistant NSCLC cells by targeting EGFR, MET, and AKT and inducing ROS generation and caspase activation. Further studies on DB can improve the treatment of chemotherapy-resistant NSCLC through the development of effective DB-based anticancer agents.
- Published
- 2024
- Full Text
- View/download PDF